Acute Myeloid Leukemia -Epidemiology Forecast to 2027

Acute Myeloid Leukemia -Epidemiology Forecast to 2027

Category

Pharmaceuticals

Published Date

1st Feb 2018

Pages

50

Choose License

Final Price

DelveInsight's "Acute Myeloid Leukemia (AML) - Epidemiology Forecast, 2027” report provides a comprehensive analysis of the Acute Myeloid Leukemia (AML) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2027

Acute Myeloid Leukemia (AML) Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Acute Myeloid Leukemia (AML) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Acute Myeloid Leukemia (AML) outlook. It also includes the explanation of changing trends of epidemiology outlining the Acute Myeloid Leukemia (AML) scenario.

Acute Myeloid Leukemia (AML) Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Acute Myeloid Leukemia (AML) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Acute Myeloid Leukemia (AML) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Acute Myeloid Leukemia (AML) Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Acute Myeloid Leukemia (AML)

Key assessments
• Patient Segmentation in Acute Myeloid Leukemia (AML)
• Acute Myeloid Leukemia (AML) Risk & Burden
• Factors driving growth in a specific Acute Myeloid Leukemia (AML) patient population
1. Report Introduction
2. Acute Myeloid Leukemia (AML) Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Acute Myeloid Leukemia (AML) in 2017
2.2. Patient Share Distribution of Acute Myeloid Leukemia (AML) in 2027
3. Disease Background and Overview: Acute Myeloid Leukemia (AML)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Acute Myeloid Leukemia (AML) in 7MM
4.3. Total Prevalent/ Incident Patient Population of Acute Myeloid Leukemia (AML) in 7MM – By Countries
5. Epidemiology of Acute Myeloid Leukemia (AML) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML)
5.1.3. Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) *
5.1.4. Sex- Specific Cases of the Acute Myeloid Leukemia (AML)*
5.1.5. Diagnosed Cases of the Acute Myeloid Leukemia (AML)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML)
5.4.3. Sub-Type Specific cases of the Acute Myeloid Leukemia (AML)*
5.4.4. Sex- Specific Cases of the Acute Myeloid Leukemia (AML)*
5.4.5. Diagnosed Cases of the Acute Myeloid Leukemia (AML)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML)
5.5.3. Sub-Type Specific cases of the Acute Myeloid Leukemia (AML)*
5.5.4. Sex- Specific Cases of the Acute Myeloid Leukemia (AML)*
5.5.5. Diagnosed Cases of the Acute Myeloid Leukemia (AML)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML)
5.6.3. Sub-Type Specific cases of the Acute Myeloid Leukemia (AML)*
5.6.4. Sex- Specific Cases of the Acute Myeloid Leukemia (AML)*
5.6.5. Diagnosed Cases of the Acute Myeloid Leukemia (AML)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML)
5.7.3. Sub-Type Specific cases of the Acute Myeloid Leukemia (AML)*
5.7.4. Sex- Specific Cases of the Acute Myeloid Leukemia (AML)*
5.7.5. Diagnosed Cases of the Acute Myeloid Leukemia (AML)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML)
5.8.3. Sub-Type Specific cases of the Acute Myeloid Leukemia (AML)*
5.8.4. Sex- Specific Cases of the Acute Myeloid Leukemia (AML)*
5.8.5. Diagnosed Cases of the Acute Myeloid Leukemia (AML)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML)
5.9.3. Sub-Type Specific cases of the Acute Myeloid Leukemia (AML)*
5.9.4. Sex- Specific Cases of the Acute Myeloid Leukemia (AML)*
5.9.5. Diagnosed Cases of the Acute Myeloid Leukemia (AML)
6. Unmet Needs of the Acute Myeloid Leukemia (AML)
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific
Table 1: Total Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in 7MM
Table 2: Total Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in United States (2016-2027)*
Table 5: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in United States (2016-2027)*
Table 6: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in United States (2016-2027)
Table 7: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in Germany (2016-2027)
Table 8: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in Germany (2016-2027) *
Table 9: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in Germany (2016-2027) *
Table 10: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in Germany (2016-2027)
Table 11: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in France (2016-2027)
Table 12: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in France (2016-2027) *
Table 13: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in France (2016-2027) *
Table 14: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in France (2016-2027)
Table 15: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in Italy (2016-2027)
Table 16: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in Italy (2016-2027) *
Table 17: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in Italy (2016-2027) *
Table 18: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in Italy (2016-2027)
Table 19: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in Spain (2016-2027)
Table 20: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in Spain (2016-2027) *
Table 21: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in Spain (2016-2027) *
Table 22: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in Spain (2016-2027)
Table 23: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in UK (2016-2027)
Table 24: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in UK (2016-2027) *
Table 25: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in UK (2016-2027) *
Table 26: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in UK (2016-2027)
Table 27: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in Japan (2016-2027)
Table 28: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in Japan (2016-2027) *
Table 29: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in Japan (2016-2027) *
Table 30: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in Japan (2016-2027)

Get Free Sample

You can get a FREE sample of any report. Just click the "Free Sample" link.

Explore Latest Reports

If you have any special requirement or looking for more discounts, Kindly contact our sales team

Contact Us